A Multi-Centre, Real-World Study on the Efficacy of PureDelivery® LAN (CatarClear®) for the Non-Surgical Management of Cataracts in Companion Animals in Singapore

Purpose: To evaluate the real-world efficacy and usability of PureDelivery® LAN (CatarClear®), a topical proprietary lanosterol (LAN) nano-formulation, for the non-surgical management of naturally occurring cataracts in companion animals. Materials and Methods: About 100 dogs and a smaller cohort of other small animal pets (e.g., cats, rabbits) diagnosed with cataracts of varying stages and etiologies. A clinical data collection study was conducted over twelve months across multiple veterinary practices in Singapore. Over 10 participating veterinary surgeons treated animals with PureDelivery® LAN (CatarClear®), administered topically twice daily for a minimum of six weeks. Efficacy was assessed based on a predefined categorical scale that is significant improvement, slight improvement, no improvement, through ophthalmic examination. Data on ease of administration and overall recommendations were also collected. Findings: Of the treated animals, 98% showed measurable improvement in cataract presentation following the treatment regimen. The improvement was categorized as significant in a notable portion of cases, particularly those with early-stage cataracts. The formulation was reported by veterinarians to be easily administered by pet owners. This study demonstrates that PureDelivery® LAN (CatarClear®) is a highly effective, non-invasive therapeutic option for managing cataracts in companion animals, especially in cases where ophthalmologic surgery is contra-indicated due to age, health risks, anaesthesia concerns, or financial constraints. Unique Contribution to Theory, Practice and Policy: Future studies should be designed as randomized, controlled, and blinded trials. Incorporating objective measures like digital image analysis of lens opacity, electroretinography (ERG), and more detailed visual obstacle course testing would strengthen the findings (20, 21). Longitudinal studies are also warranted to assess the long-term efficacy, safety, and potential for cataract recurrence after cessation of treatment across a wider range of species.